GUT MICROBIOTA COMPOSITION AND ITS METABOLITES CHANGES IN PATIENTS WITH ATHEROSCLEROSIS AND ATRIAL FIBRILLATION.

Objective: The aim: To check changes of gut microbiota composition and its metabolites in atherosclerosis (AS) patients with or without atrial fibrillation (AF) and special connections between them and important clinic and laboratory features of investigated groups.

Patients And Methods: Materials and methods: 300 patients were investigated. All investigated were divided into 3 groups: control group (CG) - 27 patients without AS and arrhythmias; mean group - 149 patients with AS but without arrhythmias; comparable group - 124 patients with AS and AF paroxysm.

Alpha-Lipoic Acid as a Means of Influence on Systemic Inflammation in Type 2 Diabetes Mellitus Patients with Prior Myocardial Infarction.

Patients with combined coronary heart disease and diabetes mellitus make up a growing segment of the population and require a comprehensive treatment approach. Patients with concurrent diabetes mellitus and coronary heart disease have a worse projection. Under these conditions, the incidence of recurrent myocardial infarction, early disability due to complications, and the risk of coronary death are increased.

Normalization of heart rate variability with taurine and meldonium complex in post-infarction patients with type 2 diabetes mellitus.

The purpose of this study is to scrutiny the Dynamics of heart rate variability (HRV) in patients with PICS with 2nd type DM against the background of Taurine (TN) and meldonium (ME). The results of the investigations prove the decrease of the oxidative stress, which is basis of DACN, under the influence of sulfur-containing amino acid taurine (TN), and meldonium (ME) - a competitive inhibitor of gamma-butyrobetaine hydroxylase. Biochemical mechanisms of synergistic action of ME and TN are also described.

Treatment with EPs 7630, a Root Extract, Is Effective and Safe in Patients with the Common Cold: Results From a Randomized, Double Blind, Placebo-Controlled Clinical Trial.

Background: EPs 7630 was shown to be effective and safe in the treatment of acute respiratory tract infections such as acute bronchitis, acute rhinosinusitis, and acute tonsillopharyngitis. A clinical trial was conducted to investigate its efficacy and safety in the common cold.

Methods: In this multicenter, randomized, double-blind phase 3 clinical trial, 105 adults suffering from common cold symptoms were randomized to a thrice-daily administration of either 1 film-coated tablet containing 40 mg EPs 7630 or matched placebo for a treatment period of 10 days.

Efficacy and Tolerability of High-dose Pelargonium Extract in Patients With the Common Cold.

Context • The common cold (CC) is usually caused by a viral infection. Antibiotics are often prescribed unnecessarily for it, although no evidence exists for any benefit in the CC. Effective alternatives are needed.